1. At a Glance – Blink and You’ll Miss the Drama
₹96,567 crore market cap. Stock price chilling at ₹1,157, down ~9.5% in the last three months like it’s avoiding eye contact with investors. Trailing P/E of ~17.3 when the industry median is flirting with ~29. ROCE a healthy 22.7%, ROE at 18%, debt-to-equity a polite 0.16 (not zero, but well-behaved).
Latest quarterly numbers? Sales at ₹8,753 crore, up 4.4% YoY, but PAT slipped ~14.4% YoY to ~₹1,190 crore. EPS for the quarter at ₹14.50. Translation: revenue still jogging, profits stopped for water.
Dr Reddy’s today looks like that topper who still scores well but no longer shocks the class. Is this a temporary breather or a sign of generics fatigue? Let’s put on the auditor glasses and dig. Curious already?
2. Introduction – From Generic Gladiator to Corporate Adulting
Dr Reddy’s has been around long enough to see multiple pharma cycles: patent cliffs, USFDA love-hate letters, Russia surprises, COVID miracles, and now… biosimilars, injectables, and niche launches.
Once upon a Dalal Street bedtime story, Dr Reddy’s was the poster child of Indian generics in the US. File ANDAs, win first-to-file, mint money, repeat. That playbook still exists, but margins are no longer falling from the sky.
FY22 revenue mix shows ~83% from Global Generics, ~14% from Pharmaceutical Services & Active Ingredients (PSAI), and a tiny ~2% from proprietary products. The company has deliberately reduced risky bets, sold off non-core assets, and tightened R&D spends from 13% of revenue in FY18 to ~8% by FY22.
Sounds mature. But maturity in pharma often means slower excitement. Investors love adrenaline. Dr Reddy’s is now serving multivitamins. Is that bad? Or just… boring? Let’s see.
3. Business Model – WTF Do They Even Do?
Think of
